JCDZRec'd PCT/PTO 2 1 MAR 2002

FORM PTO-1390 U.S. DEPARTM COMMERCE PATENT AND TRADEMARK OFFICE 'S DOCKET NUMBER (REV. 11-2000) Z70601-1 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/GB00/03556 September 18, 2000 September 21, 1999 TITLE OF INVENTION Quinazoline Compounds and Phrmaceutical Compositions Containing Them APPLICANT(S) FOR DO/EO/US ASTRAZENECA AB Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. d. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. **K**  $\Box$ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. 14. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. 16. A change of power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 17. A second copy of the published international application under 35 U.S.C. 154(d)(4). 18. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 19. 20. Other items or information:

JC10 Rec'd PCT/PTO 2 1 MAR 2002

	U.S. APPLICATION NO (if the	S. APPLICATION NO. (If known seeds one 18 (1994) INTERNATIONAL APPLICATION NO. PCT/GB00/03556				ATTORNEY'S DOCKET NUMBER Z70601-1			
	21. The following	. The following fees are submitted:				CULATIONS	PTO USE ONLY		
	BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):								
	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00								
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00								
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00								
	International preliminary examination fee (37 CFR 1.482) paid to USPTO								
	and all claims satisfied provisions of PCT Article 33(1)-(4)					0.00			
					2 00				
	months from the earl	urcharge of \$130.00 for furnishing the oath or declaration later than 20 anoths from the earliest claimed priority date (37 CFR 1.492(e)).							
	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$				
	Total claims	- 20 =	_	x \$18.00	\$		ļ		
÷	Independent claims	-3 =	1. 11.	x \$80.00 + \$270.00	\$				
MULTIPLE DEPENDEN			ENT CLAIM(S) (if applicable)		\$	<del></del>	<del> </del>		
-	TOTAL OF ABOVE CALCULATIONS =  Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above								
	are reduced by 1/2.				\$				
1	D : C CO1:	SUBTOTAL =							
. III	Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).					•			
TOTAL NATIONAL FEE = \$									
կու կա	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$40.0					0.00			
<del></del>	TOTAL FEES ENCLOSED =				\$ 90	0.00			
W W	Henn that					unt to be efunded:	\$		
						charged:	\$		
i	<ul> <li>a. A check in the amount of \$ to cover the above fees is enclosed.</li> <li>b. Please charge my Deposit Account No. 26-0166 in the amount of \$ 900.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</li> <li>c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 26-0166 . A duplicate copy of this sheet is enclosed.</li> </ul>								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit car information should not be included on this form. Provide credit card information and authorization on PTO-2									
	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.								
	SEND ALL CORRESPONDENCE TO:						1 1 7-61-02		
	AstraZ	AstraZeneca Pharmaceuticals SIGNAT				JRE()			
						George A. Gilbert			
		Patent Administrator NAME							
		1800 Concord Pike					35,881		